Sophia Gayle PhD

Sophia Gayle trained in Tian Xu’s lab at the Yale School of Medicine establishing forward genetic transposon technologies in human embryonic stem cells. She went on to become a Senior Research Scientist at LAM Therapeutics in Guilford, CT. At LAM, Sophia worked on the repurposing of clinical-stage drugs for rare disease and cancer indications as well as on the preclinical development of one of LAM Therapeutics’ lead compounds for Non-Hodgkin lymphoma. Currently, Sophia serves as Associate Director of Biology for Cybrexa Therapeutics in New Haven, CT. At Cybrexa, Sophia assists in overseeing the preclinical development of Cybrexa’s novel tumor-targeting alphabet technology and DNA Damage Response inhibitor portfolio for solid tumor indications.